MANAGEMENTUL PACIENȚILOR CU BOLI HEPATICE PE LISTA DE AȘTEPTARE PENTRU TRANSPLANT HEPATIC: UN IMPACT MAJOR ASUPRA SUCCESULUI FICATULUI TRANSPLANTAT
DOI:
https://doi.org/10.52692/1857-0011.2021.3-71.29Cuvinte cheie:
Transplant hepatic, insuficiență hepatică acută și cronicăRezumat
Rezultatele transplantului hepatic sunt excelente, cu rate de supraviețuire de peste 90 și 80% la 1 și 5 ani, respectiv. Succesul transplantului hepatic a dus la o creștere a indicațiilor pentru transplant hepatic. În general, prioritățile sunt acordate pacienților cirotici cu un model ridicat pentru boala hepatică în stadiu terminal scorul (MELD) pe principiul celui mai bolnav mai întâi și la pacienții cu carcinom hepatocelular (HCC) pe principiul de puncte prioritare în funcție de mărimea și numărul de noduli ai HCC. Aceste criterii pot duce la o „concurență” pe lista de așteptare între pacienții de mai sus și cei care sunt cirotici și au un scor MELD intermediar sau cu bolile hepatice de altă etiologie care pun viața în pericol. Pentru acest ultim grup de pacienți, „excepție MELD” punctele pot fi acordate în mod arbitrar.Referințe
Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acuteon-chronic liver failure grade 3. J Hepatol. 2017;67:708–15
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–31
Clinical Practice EASL Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–81
Crespo G, Trota N, Londono MC, Mauro E, Balielas C, Castells L, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol. 2018
Debette-Gratien M, Tabouret T, Antonini M-T, Dalmay F, Carrier P, Legros R, et al. Personalized adapted physical activity before liver transplantation: acceptability and results. Transplantation. 2015;99(1):145–50
Dutkowski P, Linecker M, DeOliveira ML, Mullhaupt B, Clavien PA. Challenges to liver transplantation and strategies to improve outcomes. Gastroenterology. 2015;148:307–23
Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including a-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94
EASL. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016; 64:433–85.
ELTR report. http://www.eltr.org.
Felmlee DJ, Coilly A, Chung RT, Samuel D,Baumert TF. New perspectives for preventing hepatitis C virusliver graft infection. Lancet Infect Dis. 2016;16: 735–45
Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute on chronic liver failure: syndrome and effects on prognosis. Hepatology. 2015;62:243–52
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26
Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol. 2018;113:235–4254 Buletinul AȘM
Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease score optimize prediction of Samuel and Coilly BMC Medicine (2018) 16:113 Page 4 of 5 mortality among patients awaiting liver transplantation. Gastroenterology. 2011;140:1952–60
Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, Samuel D, Saliba F. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol. 2012;56(1):95–102
Levesque E, Saliba F, Ichaï P, Samuel D. Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. J Hepatol. 2014;60:570–8
Manns M, Samuel D, Gane EJ, Mutimer D, Mc-Caughan G, Buti M, Prieto M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, openlabel, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97
Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011; 365:1790–800
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9
Nadim MK, DiNorcia J, Ji L, Groshen S, Levistsky J, Sung R, et al. Inequity in organ allocatin for patients awaiting liver transplantation: rationale for uncapping the model for end stage liver disease. J Hepatol. 2017;67:517–25
Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Mortality on the liver transplant waiting list: unintended policy consequences and model for end stage liver disease (MELD) inflation Hepatology. 2015;61:285–91
Petrowsky H, Rana A, Kaldas FM, Sharma A, Hong JC, Agopian VG, et al. Liver transplantation in highest acuity recipients. Identifying factors for avoiding futility. Ann Surg. 2014;259:1186–94
Sharma P, Schaubel DE, Gong Q, Guidinguer M, Merion RM. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Hepatology. 2012; 55:192–8
Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of akphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129–37
Weil D, Levesque E, McPhall M, Cavalazzi R, Theocaridou E, Cholongitas E, et al. Prognosis of cirrhotic patients admitted to intensive care unit: a metaanalysis. Ann Int Care. 2017;7:33
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease score and allocation of donor livers. Gastroenterology. 2003;124:91–6
Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Non-alcoholic steatohepatitis is the second leading etiology of liver diseases among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403
Saliba F, Ichaï P, Levesque E, Samuel D. Cirrhotic patients in the ICU: prognostic markers and outcome. Curr Opin Crit Care. 2013;19(2):154–60.
Descărcări
Publicat
Număr
Secțiune
Licență
Copyright (c) 2022 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.
